{
    "nctId": "NCT02441946",
    "briefTitle": "A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer",
    "officialTitle": "neoMONARCH: A Phase 2 Neoadjuvant Trial Comparing the Biological Effects of 2 Weeks of Abemaciclib (LY2835219) in Combination With Anastrozole to Those of Abemaciclib Monotherapy and Anastrozole Monotherapy and Evaluating the Clinical Activity and Safety of a Subsequent 14 Weeks of Therapy With Abemaciclib in Combination With Anastrozole in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Hormone Receptor Positive Tumor, Early-Stage Breast Carcinoma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 224,
    "primaryOutcomeMeasure": "Percent Change From Baseline to 2 Weeks in Ki67 Expression",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Have postmenopausal status.\n* Adenocarcinoma of the breast.\n* Breast tumor \u22651 centimeter (cm) in diameter, HR+, HER2-.\n* Neoadjuvant endocrine monotherapy is deemed to be a suitable therapy.\n* Primary breast cancer that is suitable for baseline core biopsy.\n* Have adequate organ function.\n\nExclusion Criteria:\n\n* Bilateral invasive breast cancer.\n* Metastatic breast cancer (local spread to axillary lymph nodes is permitted).\n* Inflammatory breast cancer.\n* Prior systemic therapy or radiotherapy for invasive or non-invasive breast cancer in the same breast as currently being treated.\n* Prior radiotherapy to the ipsilateral chest wall for any malignancy.\n* Prior anti-estrogen therapy.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}